Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The retention of galactose-deficient IgA1 (Gd-IgA1) in the mesangium is central to IgA nephropathy (IgAN), but its intracellular fate remains unclear. Here, we show that transferrin receptor 1 (TfR1) mediates Gd-IgA1 uptake into mesangial cell lysosomes, where it forms non-digestible aggregates, disrupts lysosomal function, and triggers inflammatory responses. In renal biopsies from IgAN patients, IgA1 aggregates co-localize with TfR1 within lysosomes. In male mice, TfR1 overexpression enhanced lysosomal accumulation of Gd-IgA1, whereas TfR1 knockdown reduced it. Mechanistically, acidic pH strengthens TfR1-Gd-IgA1 binding via the galactose-deficient hinge region and residue R276. While we acknowledge that sialylation commonly found in patient-derived IgA1 might influence TfR1 binding and that other receptors, such as ASGPR, were not evaluated, our findings nonetheless reveal a lysosome-centered mechanism in IgAN and highlight receptor-mediated retention of Gd-IgA1 as a potential therapeutic target.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12219878PMC
http://dx.doi.org/10.1038/s41467-025-60819-wDOI Listing

Publication Analysis

Top Keywords

galactose-deficient iga1
8
transferrin receptor
8
iga nephropathy
8
tfr1
5
lysosome-mediated aggregation
4
aggregation galactose-deficient
4
iga1
4
iga1 transferrin
4
receptor links
4
links iga
4

Similar Publications

Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy.

Clin J Am Soc Nephrol

September 2025

Kidney Division, Peking University First Hospital, Peking University Institute of Nephrology; Key Laboratory of Kidney Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, China.

Background: The Therapeutic Effects of Steroids in IgA Nephropathy Global (TESTING) trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with Immunoglobulin A Nephropathy (IgAN). Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgAN pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear.

View Article and Find Full Text PDF

Differential Expression of ATP6V1D and Its Diagnostic Potential in IgA Nephropathy.

Curr Med Sci

September 2025

Department of Agriculture and Biotechnology, Hunan University of Humanities, Science and Technology, Loudi, 417000, China.

Objective: IgA nephropathy (IgAN) is the most prevalent form of primary glomerular disease. However, its diagnosis is contingent on kidney biopsy. Therefore, noninvasive biomarkers are urgently needed for diagnosis.

View Article and Find Full Text PDF

Membranous nephropathy as a segmental pattern with solitary immunoglobulin A deposition: a case report.

CEN Case Rep

August 2025

Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8461, Japan.

A 67-year-old man with a history of hypertension and dyslipidemia presented with edema and heavy proteinuria. Light microscopic analysis of kidney biopsy revealed a diffuse segmental membranous feature. Immunofluorescence stain was segmentally positive for IgA, galactose-deficient IgA1, both κ and λ light chains, and C3 along the glomerular capillary walls, but negative for IgG, IgM, or C1q.

View Article and Find Full Text PDF

IgA nephropathy (IgAN) is a prevalent primary glomerular disease and a major contributor to end-stage renal disease (ESRD). Budesonide Enteric Capsules (Nefecon®) are the first treatment approved by the U.S.

View Article and Find Full Text PDF

Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy.

Nephrol Dial Transplant

August 2025

Biobank of Peking University First Hospital, Peking University First Hospital; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Health Science Center, Peking University, Beijing, China.

Background And Hypothesis: Leukemia inhibitory factor (LIF) has been implicated in the production of galactose-deficient IgA1 and development of renal fibrosis, and has emerged in several genome-wide association studies (GWAS) studies as a hotspot gene of IgAN. Therefore, we hypothesis that urinary LIF could predict the renal prognosis and/or treatment response to immunosuppressive therapy in IgAN patients.

Methods: A prognostic study was conducted in a retrospective cohort of 506 biopsy-confirmed IgAN patients.

View Article and Find Full Text PDF